Status:
RECRUITING
Evaluation for Therapeutic Plasma Exchange for Immune Mediated Neurological Disease
Lead Sponsor:
Al-Azhar University
Conditions:
Neurological Autoimmune Diseases
Eligibility:
All Genders
Brief Summary
The goal of this observational study is to Evaluation of Therapeutic Plasma Exchange for Immune-Mediated Neurological Diseases in a Sample of Egyptian Patients: An Experience at Al-Azhar University Ho...
Detailed Description
Therapeutic plasma exchange (TPE) is recommended as Class I therapies by the American Society for Apheresis (ASFA) guidelines and are widely used as first-line therapies for the treatment of acute neu...
Eligibility Criteria
Inclusion
- 1\. All neurological patients irrespective of age who will undergo TPE. 2.All new and relapse cases that meet the ASFA guidelines and where TPE is the first and/or second line of therapy
Exclusion
- 1\. Individuals with contraindications to therapeutic plasma exchange, such as hemodynamic unstable, hypocalcaemia, allergy to fresh frozen plasma or albumin.
- Patients who will undergo fewer than five cycles of TPE and not complete the procedure.
- Patients with non-neurological disorders.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07197099
Start Date
January 1 2025
End Date
December 31 2025
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Azhar University Hospitals
Cairo, Egypt